ELAPRASE
Biological
Takeda Pharmaceuticals U.S.A., Inc.
Total Payments
$30.1M
Transactions
3,871
Doctors
1,223
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.4M | 376 | 119 |
| 2023 | $3.1M | 430 | 214 |
| 2022 | $5.0M | 494 | 169 |
| 2021 | $2.9M | 326 | 89 |
| 2020 | $3.1M | 282 | 18 |
| 2019 | $4.3M | 381 | 78 |
| 2018 | $4.7M | 494 | 79 |
| 2017 | $4.5M | 1,088 | 576 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $29.5M | 1,768 | 98.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $218,947 | 85 | 0.7% |
| Consulting Fee | $190,926 | 84 | 0.6% |
| Travel and Lodging | $89,492 | 267 | 0.3% |
| Food and Beverage | $47,189 | 1,381 | 0.2% |
| Education | $21,879 | 279 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $13,750 | 7 | 0.0% |
Payments by Type
Research
$29.5M
1,768 transactions
General
$582,183
2,103 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFASE ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PATIENTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT | Takeda Pharmaceuticals U.S.A., Inc. | $12.3M | 1 |
| AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFASE ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PATIENTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT | Shire North American Group Inc | $8.9M | 2 |
| AN OPEN-LABEL EXTENSION TO STUDY HGT-HIT-045 EVALUATING LONG-TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL ADMINISTRATION OF IDURSULFASE-IT IN PEDIATRIC PATEINTS WITH HUNTER SYNDROME WHO DEMONSTRATE EVIDENCE OF CENTRAL NERVOUS SYSTEM INVOLVEMENT AND | Takeda Pharmaceuticals U.S.A., Inc. | $2.8M | 0 |
| A CONTROLLED, RANDOMIZED, TWO-ARM, OPEN-LABEL, ASSESSOR-BLINDED, MULTICENTER STUDY OF INTRATHECAL IDURSULFASE-IT ADMINISTERED IN CONJUNCTION WITH INTRAVENOUS ELAPRASE IN PEDIATRIC PATIENTS WITH HUNTER SYNDROME AND EARLY COGNITIVE IMPAIRMENT | Shire North American Group Inc | $1.7M | 0 |
| AN OPEN-LABEL EXTENSION TO STUDY HGT-HIT-045 EVALUATING LONG-TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL ADMINISTRATION OF IDURSULFASE-IT IN PEDIATRIC PATEINTS WITH HUNTER SYNDROME WHO DEMONSTRATE EVIDENCE OF CENTRAL NERVOUS SYSTEM INVOLVEMENT AND | Shire North American Group Inc | $1.5M | 0 |
| An Open Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment | Shire North American Group Inc | $638,451 | 0 |
| A GLOBAL, MULTI-CENTER, LONG-TERM, OBSERVATIONAL SURVEY OF PATIENTS WITH HUNTER SYNDROME MUCOPOLYSACCHARIDOSIS II | Takeda Pharmaceuticals U.S.A., Inc. | $377,688 | 0 |
| A GLOBAL, MULTI-CENTER, LONG-TERM, OBSERVATIONAL SURVEY OF PATIENTS WITH HUNTER SYNDROME MUCOPOLYSACCHARIDOSIS II | Shire North American Group Inc | $294,559 | 0 |
| HUNTER OUTCOME SURVEY: A GLOBAL, MULTI-CENTER, LONG-TERM, OBSERVATIONAL REGISTRY OF PATIENTS WITH HUNTER SYNDROME (MUCOPOLYSACCHARIDOSIS TYPE II, MPS II) | Takeda Pharmaceuticals U.S.A., Inc. | $245,027 | 0 |
| EFFECT OF ENZYME REPLACEMENT THERAPY ON AIRWAY ABNORMALITIES IN HUNTER SYNDROME | Takeda Pharmaceuticals U.S.A., Inc. | $219,508 | 0 |
| TAK-665-4003: An Open-label, Multicenter, Phase 4 Study to Assess the Effects of a Prophylactic Immune Tolerizing Regimen in MPS II Treatment-Na\00EFve Patients Planned to Receive ELAPRASE Who Are at Risk of Developing Persistent Neutralizing Antibodies | Takeda Pharmaceuticals U.S.A., Inc. | $151,146 | 0 |
| TAK-665-4003: AN OPEN-LABEL, MULTICENTER, PHASE 4 STUDY TO ASSESS THE EFFECTS OF A PROPHYLACTIC IMMUNE TOLERIZING REGIMEN IN MPS II TREATMENT-NAVE PATIENTS PLANNED TO RECEIVE ELAPRASE WHO ARE AT RISK OF DEVELOPING PERSISTENT NEUTRALIZING ANTIBODIES | Takeda Pharmaceuticals U.S.A., Inc. | $81,880 | 0 |
| EFFECT OF ENZYME REPLACEMENT THERAPY ON AIRWAY ABNORMALITIES IN HUNTER SYNDROME | Shire North American Group Inc | $73,251 | 0 |
| Immunophenotyping of patients with MPS II treated with enzyme replacement therapy | Takeda Pharmaceuticals U.S.A., Inc. | $60,150 | 0 |
| NEWBORN SCREENING FOR MPS II HUNTER SYNDROME | Shire North American Group Inc | $50,994 | 0 |
| A LONG-TERM, OPEN-LABEL, MULTICENTER, PHASE IV STUDY TO ASSESS LONGITUDINAL CHANGES ON HEIGHT AND WEIGHT IN PATIENTS WITH MPS II WHO ARE RECEIVING ELAPRASE AND STARTED TREATMENT WITH ELAPRASE AT <6 YEARS OF AGE | Takeda Pharmaceuticals U.S.A., Inc. | $49,319 | 0 |
| LONGITUDINAL STUDIES OF BRAIN STRUCTURE AND FUNCTION IN MUCOPOLYSACCHARIDOSIS TYPE II | Shire North American Group Inc | $38,703 | 0 |
| CEREBRAL SPINAL FLUID BIOMARKERS IN MPS | Takeda Pharmaceuticals U.S.A., Inc. | $33,225 | 0 |
| Hunter Outcome Survey: A Global, Multi-Center, Long-Term, Observational Registry of Patients With Hunter Syndrome (Mucopolysaccharidosis Type II, MPS II) | Takeda Pharmaceuticals U.S.A., Inc. | $31,361 | 0 |
| A Long Term, Open Label, Multi-Center, Phase IV Study of the Effect of Elaprase on Height and Weight in Participants with MPS II Who Started Treatment With Elaprase at <6 Years of Age | Takeda Pharmaceuticals U.S.A., Inc. | $29,000 | 0 |
Top Doctors Receiving Payments for ELAPRASE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $29.5M | 1,768 |
| , MD | Clinical Genetics (M.D.) | Chicago, IL | $133,280 | 169 |
| , M.D | Clinical Genetics (M.D.) | Santurce, PR | $109,773 | 162 |
| , MD | Pediatrics | Chapel Hill, NC | $71,370 | 72 |
| , MD | Pediatric Otolaryngology | Madison, CT | $49,961 | 68 |
| , MD | Pediatric Gastroenterology | Oakland, CA | $28,948 | 44 |
| , MD | Clinical Genetics (M.D.) | Phoenix, AZ | $16,676 | 15 |
| , MD | Clinical Genetics (M.D.) | Minneapolis, MN | $15,784 | 7 |
| , MD | Neurological Surgery | Minneapolis, MN | $14,357 | 6 |
| , MD | Neurological Surgery | Chicago, IL | $10,337 | 6 |
| , MD | Pediatric Otolaryngology | Saint Louis, MO | $9,917 | 23 |
| , M.D | Student in an Organized Health Care Education/Training Program | Chicago, IL | $9,459 | 3 |
| , D.O | Pediatrics | Lebanon, NH | $7,440 | 8 |
| Richard Rauck | — | Winston Salem, NC | $5,363 | 6 |
| , MD | Surgical Critical Care | Newton Centre, MA | $5,085 | 1 |
| , M.D | Pulmonary Disease | New York, NY | $3,400 | 2 |
| , MD | Anesthesiology | Indianapolis, IN | $3,228 | 4 |
| Deepa Rajan | Pediatrics | Detroit, MI | $3,153 | 1 |
| , MD | Clinical Genetics (M.D.) | New York, NY | $2,800 | 1 |
| , M.D | Clinical Genetics (M.D.) | Philadelphia, PA | $2,764 | 8 |
| , MD | Pediatrics | Orange, CA | $2,545 | 2 |
| Priya Kishnani | Pediatrics | Durham, NC | $2,250 | 2 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Washington, DC | $1,950 | 1 |
| , M.D | Internal Medicine | Detroit, MI | $1,270 | 2 |
| , MD | Clinical Genetics (M.D.) | Orange, CA | $1,242 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $30.1M
- Total Doctors 1,223
- Transactions 3,871
About ELAPRASE
ELAPRASE is a biological associated with $30.1M in payments to 1,223 healthcare providers, recorded across 3,871 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2017 to 2024. In 2024, $2.4M was paid across 376 transactions to 119 doctors.
The most common payment nature for ELAPRASE is "Unspecified" ($29.5M, 98.1% of total).
ELAPRASE is associated with 20 research studies, including "AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFASE ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PATIENTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT" ($12.3M).